Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB002 in advanced solid tumors
NCT05924906Phase 1Not yet recruiting
- Sponsor
- NeoLogics Bioscience
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of NB002 in solid tumor (6 arms), sponsored by NeoLogics Bioscience. Primary endpoints: Number of participants with adverse events (AE), serious adverse events (SAE) up to 12 months and Number of participants with dose-limiting toxicity (DLT) at 21 days. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
NB002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05924906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924906.